"The number one advantage regarding Nevisense is that it backs up my decision and provides me with more certainty in whether or not to excise a lesion"Dr. Isabel Gahlen, Ludwigsburg, Germany
SciBase publishes the Annual report for 2018September 6, 2019
SciBase hereby announces that the Annual report for 2018 is available at the Company’s website www.scibase.com.
SciBase announces first sale within the new Skin Barrier applicationSeptember 3, 2019
SciBase today announces the first sale and shipment of SciBase products for the evaluation of skin barrier function. The first shipment is to a prestigious hospital in Japan for research into skin barrier function in infants.
Bulletin from annual general meeting of SciBase Holding AB (publ) on 16 May 2019May 16, 2019
At the annual general meeting of SciBase Holding AB (publ) on 16 May 2019 in Stockholm the shareholders adopted the below resolutions.
Letter from the CEO, SciBase April 2019April 17, 2019
Dear SciBase shareholders,
New study opens up new applications for SciBase’s product Nevisense
SciBase announces skin barrier testing collaboration with leading Swiss research centerDecember 6, 2018
Clinical Guideline for Nevisense published in GermanyNovember 19, 2018
The following people have been appointed as members of SciBase Holding’s election committee for the Annual General Meeting in 2019:November 5, 2018
New US Study: Nevisense shows significant positive impact on clinical decision makingNovember 2, 2018
- Load more news...